Introduction
Gene therapy has become an increasingly important strategy for treating a variety of human diseases, including inherited disorders, viral infections and cancer. A number of studies have shown that introduction of various genes into tumor cells can lead to suppression of tumor growth. 1 A common method for delivering genetic material into cells is that which uses cationic liposomes. Since Brigham and co-workers 2 first reported this technique, the use of cationic lipids complexed to plasmid expression vectors has become one of the most promising non-viral methods for in vivo gene delivery. 1, 3, 4 Although cationic liposomal vectors mediate effective gene transfer, tissue specific in vivo DNA delivery is still a major challenge for gene therapy. To date, tissue-specific targeting of cationic liposomal DNA has been accomplished by two distinct techniques. The first method involves transfection of selected tissues, such as nasal epithelium, 5 arterial endothelium, 6 lung 7, 8 or tumors 9 by locally administering the complexes within defined regions. This method has proven to be a viable option for the clinical treatment of several diseases, including cystic fibrosis and cancer. 5, 10, 11 A second method used to enhance the specificity of gene therapy is by coupling cell-binding ligands, such as folic acid (FA), [12] [13] [14] [15] transferrin 16 or carbohydrates 17 to liposomes for the purpose of combining the intrinsic activities of lipids with the receptor-mediated uptake properties of the applied ligand.
We have been interested in the use of folic acid (FA) as a targeting ligand to deliver attached therapeutic and imaging agents to cancer cells that over-express the receptor for FA. [18] [19] [20] Because FA-linked cargos are efficiently bound and internalized by folate receptor (FR)-expressing cells, we have explored the possibility of using FA to enhance cationic liposomal vector delivery to FR-enriched tumors. Thus, in the present study we investigated the opportunity for targeting a syngeneic murine tumor in vivo by the regional administration of FA-labeled cationic liposomes. For this purpose, we first optimized and compared the amount of FA ligand required for optimal targeting of both neutral and cationic liposomes to FR-bearing cells. We then used L1210A intraperitoneal tumor-bearing DBA mice to investigate the in vivo targeting potential of our FA-labeled vectors.
Results

Optimization of folate-mediated liposome targeting
Previous studies 21 with FA-targeted liposomes had indicated that low mole fractions of a folate-polyethyleneglycol-phosphatidylethanolamine (FA-PEG-PE) conjugate were needed to successfully mediate liposome binding by FR-bearing cells. However, no investigation was ever conducted to optimize the mole fraction of this targeting component. Although we would have preferred to optimize this parameter using cationic liposome formulations, we felt that their inherent propensity to nonspecifically interact with cell membranes would have adversely affected our ability to measure folate-specific cell binding. Accordingly, we determined the optimal amount of a related FA-cysteine-PEG 3400 -distearylphosphatidylethanolamine (FA-Cys-PEG-PE; see Figure 1 ) conjugate for use in 65:35 dioleoylphosphatidylcholine/ cholesterol (DOPC/Chol) liposomes.
Increasing concentrations of FA-Cys-PEG-PE were formulated within calcein-loaded liposomes. Formulations were then incubated with FR-positive M109 cells to allow liposome binding, and the amount of cell-associated fluorescence was quantitated. As shown in Figure 2a , uptake of the fluorescent liposomes was found to critically depend on the amount of FA-Cys-PEG-PE formulated in these vesicles. Cell-associated calcein fluorescence was found to increase with increasing concentrations of FA-Cys-PEG-PE until a maximum was reached at~0.03 mole %. However, higher mole fractions of FA-Cys-PEG-PE surprisingly caused a reduction of liposome uptake.
The aforementioned observation was unexpected, but it prompted us to search for a plausible explanation. It is known that the folate molecule can form dimers, trimers and even self-assembling tubular quartets at higher concentrations. 22 Since the FR can only bind one molecule of FA, 23 such self-assembled multimers of FA would be incapable of binding to the FR. Thus, we postulated that the FA moieties in liposomes containing high mole fractions of FA-Cys-PEG-PE might actually self-assemble, thereby preventing efficient interaction with the FR. To address this issue, we conducted additional experiments that were aimed to reduce or prevent the FA moieties from interacting with each other. First, we prepared DOPC/Chol calcein liposomes with increasing amounts of the non-targetable PEG 3000 -DOPE component plus the apparent optimum mole percent of FA-Cys-PEG-PE (0.03%), and then incubated them with cultured M109 cells. As shown in Figure 2b , M109 cells had efficiently bound the fluorescent FA-linked liposomes, and the presence of up to 2 mole % of the non-targetable PEG 3000 -DOPE did not reduce their affinity for the FR-positive cultured cells. We interpret these results to suggest that the PEG component of FA-Cys-PEG-PE was not responsible for the observed reduction in cell association of liposomes formulated with high mole percentages of FA-Cys-PEG-PE.
Next, in an effort to reduce the potential interactions of neighboring folates, perhaps via a charge repulsion mechanism, we synthesized a new FA-PEG-lipid conjugate that contained a few additional charged residues inbetween the PEG and folate moieties. Thus, the novel folate -diaminopropionyl-aspartyl -cysteinyl -PEG -DOPE (FA-Dap-Asp-Cys-PEG-DOPE) component was prepared (see Figure 1 ). This conjugate was formulated at 0.01 to 2 mole % into DOPC/Chol calcein-loaded liposomes, which were subsequently incubated with M109 cells for the assessment of receptor-mediated uptake. Interestingly, the pattern of cell association of the FA-Dap-AspCys-PEG-liposomes was very similar to that of FA-Cys-PEG-liposomes (data not shown). Thus, decreased liposome binding to cells resulted for those formulations bearing the higher amounts of the FA-Dap-Asp-Cys-PEG-DOPE component. We therefore concluded that having additional negative charges located within the folate region of the targeting lipid did not change the binding potential of these liposomes to FR-bearing cells. In other words, the extra negative charges apparently failed to block the stacking of pteroate moieties from neighboring FA-Dap-Asp-Cys ligands.
Although FA is the key molecule responsible for the binding of neutral or anionic liposomes to the FR, folatedependent binding will likely be influenced by the dynamics of the PEG molecule. Thus, we thought that an understanding of the theoretical maximum and minimum PEG surface area coverage may help explain the observed dependence of liposome binding to cells at any given FA-Cys-PEG-PE concentration. For example, since FA is attached to the distal end of the flexible PEG tether, its average position from the liposome surface should be equal to the Flory radius, R F , or the average PEG-coil dimension in solution. 24 The R F is equal to aN 0.64 , where a is the size of an ethylene glycol monomer (3.5 Å ) and N is the polymerization index (75), ie the number of ethylene oxide units in the PEG chain. Hence, the R F for the PEG 3400 used in our studies is equal to 55 Å , which corresponds to a liposome surface area coverage of~95 nm 2 for each FA-Cys-PEG molecule. Assuming that the total surface area of a 100 nm liposome is approximately 3.14 × 10 4 square nanometers, 25 approximately 330 FA-Cys-PEG molecules would be required to adequately cover the entire liposomal surface. If the total number of lipids which make up the outer leaflet of these liposomes is 4.25 × 10 4 molecules, 25 roughly 0.78 or greater mole % of FA-Cys-PEG-PE would be enough to theoretically allow the folates to interact with one another and possibly dimerize or multimerize, a consequence that would prevent liposomal binding to the FR. Alternatively, if all of the PEG tethers were fully extended, the maximum possible stacking distance, L, (which equals aN, or approximately 263 Å ), would correspond to a surface area of 2173 nm 2 . Under this condition, only 14 FA-Cys-PEG-PE molecules (or the equivalent of 0.033 mol % FACys-PEG-PE in the formulation) would be needed to completely cover the surface of a liposome. Since this 'extended' PEG configuration has a lower chance of occurring over any finite time, all or most of the FA-Cys-PEG-PE molecules should be available to bind to the FR when present in the liposome at Յ0.033 mole %. Interestingly, these predictions have seemingly been confirmed in our studies (see Figure 2a) , where the greatest binding of liposomes to FR-positive cells was observed at 0.03% FA-Cys-PEG-PE. At concentrations greater than 0.033 mole %, the probability of folates interacting or multimerizing with each other likely increased with increasing amounts of FA-Cys-PEG-PE, thus causing the observed reduction of liposome binding to the FR-positive cells.
Optimization of cationic liposome/DNA complex for transgene expression in vivo
Before the onset of our folate-targeted in vitro and in vivo gene therapy investigations, we decided to determine the optimal formulation ratio of cationic lipid and DNA that could manifest the greatest transfection activity in tissues. To accomplish this task we chose to use the novel RPR209120 26, 27 /DOPE formulation for DNA complexation. Formulations prepared with increasing lipid/DNA ratios were then injected into Balb/c mice. Because it is well known that lung tissue is primarily transfected by intravenously administered cationic lipidbased DNA formulations, 28, 29 we measured the levels of luciferase activity in the lungs of the treated mice and then identified the formulation that produced the maximum transgene expression activity. As shown in Figure 3 , formulations with a nmol lipid/g DNA ratio of less than 3 yielded very large-sized particles and undetectable lung transfection activity. However, formulations prepared with a lipid/DNA ratio of 5 were found to produce the greatest level of lung transfection. Interestingly, these complexes were also smaller (~100 nm for formulations with a lipid/DNA ratio of Ն5). At lipid/DNA ratios greater than 6, the transfection efficiency decreased despite the fact that the formulation particles remained small in size. Notably, although we observed no fatalities in cohorts that received intravenous injections of the 5 nmol lipid/g DNA formulation, we did observe progressively increasing fatalities with the higher ratio formulations (e.g. greater than 50% fatalities with Ն8 nmol lipid/g DNA formulations). Since (1) liposomes with an average diameter of 100-200 nm have been shown to have the greatest tumor accumulation; 30 (2) the endocytosis pathway can accommodate only particles with a maximal diameter of 100-150 nm; 31, 32 and (3) no fatalities were observed in cohorts receiving the 5 nmol lipid/g DNA formulations, we chose to use the 5 nmol lipid/g DNA formulations for the remainder of our studies. Notably, the highest luciferase-mediated light emission was detected in tissues 24 h post administration, but the activity then decreased rapidly and reduced to 50% of maximum by 48 h. Thus, for subsequent in vivo studies we chose to measure tissue transfection activity 24 h post administration.
Effect of FA-Cys-PEG-PE content on cationic lipid mediated transfection efficiency in vitro
The optimal FA-Cys-PEG-PE mole fraction needed to produce serum-stable cationic-based liposome formulations is currently not known. We therefore explored this parameter by measuring the extent of luciferase gene transfection in FR-positive M109 cells and FR-negative 4T1 cells exposed to formulations containing the cationic lipid, RPR209120, DOPE, protamine, and increasing amounts of FA-Cys-PEG-PE (or PEG-PE). As shown in Figure 4a and b, transfection activity was found to decrease with increasing concentrations of PEG-PE when the gene complexes were incubated with the M109 or 4T1 cells in the presence of 10% serum. When FR-negative 4T1 cells were incubated with complexes containing FACys-PEG-PE, the trend remained similar to that of complexes containing the PEG-PE component (ie as expected, the transfection activity decreased with increasing concentrations of FA-Cys-PEG-PE). In contrast, transfection activity in the FR-positive M109 cells had actually increased with complexes containing between 0.1 and 0.3% of FA-Cys-PEG-PE. In fact, transfections were 10-15-fold higher than the corresponding non-targeted complexes when the liposome formulations contained the 'optimum' level of this targeting lipid. We believe that the observed decrease in activity with the non-targetable PEG-PE-containing formulations is due to the steric shielding of the vector's cationic charge from the highly anionic cell surface proteoglycans. 33 However, since the addition of FA-Cys-PEG-PE to the formulation apparently maintained or even increased the vector's overall transfection efficiency in cells expressing high levels of the FR (M109), the PEG-dependent shielding of charge interactions may have been compensated by the high affinity binding of FA to the FRs on the tumor cells.
Similar to our results with the calcein-loaded liposomes (Figure 2 ), we observed that liposome-dependent transfection activity was reduced to very low levels when high amounts of the PEG component (>1% of FA-Cys-PEG-PE) were included in the formulation. This suggested that although FA helped to bind the complexes to the FR-positive cells, high amounts of the accompanying PEG presumably hindered the ability of the cationic lipids to interact with the endosome bilayer to effectively release the DNA into the cytosolic milieu. The dilemma that such data creates is that it becomes difficult to distinguish between the role of plasmid delivery from that of transgene expression activity. The latter cannot occur without the former, but it indicates that successful delivery of the DNA into the cells may not guarantee efficient transgene expression. In summary, optimal transfection Gene Therapy efficiency may only be achieved when the proper balance between delivery of the DNA cargo inside the cell and its release from within intracellular vesicular compartments (ie endosomes) is established.
Because the physicochemical properties of liposome/ DNA complexes and their interactions with serum proteins and cells are not clearly understood, we decided to evaluate the transfection efficiency of these liposome/ DNA particles in the presence of a high level of serum. In contrast to the aforementioned transfections that were conducted in 10% serum, analogous studies conducted in the presence of 60% serum revealed that transfection activity decreased between 50-and 1000-fold (see Figure  4c ). Despite this large decrease, a three-to 400-fold level of FA-targeted enhancement was still observed with the FA-Cys-PEG-PE containing formulations relative to the PEG-PE-containing control formulations. This apparent serum-dependent reduction in transfection activity could be explained if the DNA complexes became completely coated with serum proteins, a consequence that would have changed the net surface charge on the cationic liposome/DNA complexes from positive to negative. 34 Thus, while serum proteins may have coated the nontargeted cationic vector complexes and reduced their intrinsic electrostatic cellular binding ability, the~250Å PEG spacer between FA and the lipid probably enabled the ligand to penetrate through the protein coating and made it available to bind FRs present on the cell surface.
Luciferase expression in L1210A tumors
In our laboratory, the L1210A intraperitoneal cancer in DBA mice seems to be similar to the spread of ovarian cancer in patients with advanced disease. In other words, widespread or disseminated cancer and ascites fluid develop in the peritoneal cavity. This property makes it a useful model to investigate novel experimental therapies. Thus, we have noted that the inoculation of 2 × 10 4 L1210A tumor cells into peritoneal cavity of mice consistently produced ascites fluid, large intra-abdominal tumors (~200 mg), sub-diaphragmatic tumor deposits and eventually death within~16 days.
Having recognized that FA-Cys-PEG-PE enhances cationic lipid/DNA transgene expression in vitro (relative to non-targeted complexes) only at low concentrations, we decided to evaluate the performance of these complexes in DBA mice bearing L1210A i.p. tumors. As shown in Figure 5a , i.p. injections with lipid/DNA complexes containing 0.01% FA-Cys-PEG-PE yielded the highest luciferase activity (125 ng/mg protein) in the tumor ascites fraction. This activity was approximately 10-fold lower when the liposomes did not contain a targeting moiety (i.e. when FA-Cys-PEG-PE was replaced by PEG-PE in the complex). With complexes containing higher concentrations of FA-Cys-PEG-PE (0.03-0.3%), the level of luciferase expression observed was lower (16.5 ng/mg protein) than that obtained with complexes containing 0.01% of the targeting lipid. Yet, even with complexes containing 0.03 and 0.1% FA-Cys-PEG-PE, there was still a six-to nine-fold increase in transfection activity over their corresponding non-targeted complexes containing only PEG-PE.
Luciferase activity was also measured in tumors and various peritoneal organs after the i.p. injection of RPR209120/DOPE/DNA complexes. As shown in Figure  5b , the highest luciferase activities were observed in 
inoculation of L1210A cells, groups of five mice received i.p. injections of liposome-DNA complexes containing 250 nmol of RPR209120/DOPE liposomes complexed to 50 g of a luciferase-containing plasmid. Mice were killed 24 h later, and ascites cells and selected tissues were harvested and assayed for luciferase activity, as described in Materials and methods section. (a) Luciferase activity in L1210A ascitesderived cells; (b) Luciferase activity in L1210A solid tumor and other peritoneal organs from mice treated with RPR209120/DOPE (open bars), RPR209120/DOPE/PEG-DOPE (hatched bars), or RPR209120/ DOPE/ FA-Cys-PEG-DOPE (solid bars).
tumor cell ascites followed by those with solid tumors. In both tumor forms, FA-Cys-PEG-PE increased the transfection activity over that of non-targeted complexes by eight-to 10-fold. Importantly, very low or even no luciferase activity could be detected in the surrounding peritoneal organs such as the spleen, liver and intestine (see Discussion). Thus, by using a combination of FA targeting and regional administration of the complexes, an approximate 12-50-fold increase in transfection activity of solid tumor tissue and a 500-1000-fold increase in ascites tumor cells could be achieved relative to the surrounding peritoneal organs.
Discussion
Liposome-based delivery systems have long been identified as safe and effective drug carriers that are amenable to modification with cell-specific targeting ligands. In regards to gene delivery, the most common liposomes are those prepared with various cationic lipids in combination with a fusogenic lipid, such as DOPE. 35, 36 For our investigation, we prepared FA-targeted liposomes where the folate moiety was attached to a lipid membrane anchor via a cysteinyl-PEG 3400 spacer. The Cys-PEG spacer was employed for two reasons. First, it was known that effective targeting of liposomes to cancer cells resulted when a 250 Å PEG 3400 spacer was used. 21 Secondly, it was recently shown that having an additional negative charge (such as the cysteinyl carboxylic acid) near the para-aminobenzoyl moiety of FA enhanced the binding of corresponding conjugates to FRbearing cells. 37 We began our investigations by closely examining the ability of FA to target PC/Chol liposomes to FR-positive cancer cells under conditions where the mole percentage of the FA-Cys-PEG-PE component was varied over a wide range. Surprisingly, it was found that the greatest cell association occurred when the liposomes were formulated with very low amounts of FA-Cys-PEG-PE (less than 0.03%). Theoretical calculations revealed that the folate moieties located at the distal end of the PEG spacers would likely not interact with each other at concentrations lower than 0.033%; but, at concentrations greater than 0.033%, the folate moieties of the FA-Cys-PEG-PE conjugate would be close enough to interact by possibly dimerizing or multimerizing with each other. This would consequently lead to a decrease of liposome binding to FR-positive cells. Although no direct proof for folate selfassociation was obtained in this investigation, these theoretical predictions were supported experimentally since cell-associated liposomal fluorescence was observed to progressively decrease at higher FA-Cys-PEG-PE concentrations.
It has previously been shown that co-incubation of folate-targeted liposomes with very high amounts (~1 mM) of folic acid is required to significantly reduce FR-specific cellular liposome uptake, suggesting that folate liposomes may have an unusually high affinity for FR-positive cells. 21 Indeed, we have observed similar results with our folate-targeted PC/cholesterol liposomes (data not shown). This apparent 'elevated' affinity has been explained by the fact that the large size of the liposomes and the PEG spacers enable each liposome to bind to more than one cell surface FR, thus yielding a multivalent attachment. Interestingly, we have observed that when 1 mM of folic acid was used to compete with our folatetargeted cationic liposomes, transfections were reduced by as much as 50-fold. However, when transfections of non-targeted liposomes were tested in the presence of 1 mM folic acid, a 10-fold reduction in 'non-specific' transfection was also observed. We interpreted these findings to suggest that although most of the reduction in folatetargeted transfections in the presence of high amounts of folic acid is due to reduced binding to the FRs, high concentrations of folic acid could also produce a decrease in cationic lipid/DNA complex stability (perhaps in a charge-dependent manner). Therefore, as a control for our gene transfection experiments, we have preferred to use non-targeted complexes which are identically formulated to the targeted complexes except they lack the folate moiety at the end of the PEG linker.
When the effect of FA-Cys-PEG-PE concentration was tested with the cationic lipid/DNA formulation in the presence of 10% serum, the highest targeting and transfection efficiency was observed at slightly higher levels (0.1 to 0.3%) than that required for the PC/Chol-based
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liposomes. Yet at 60% serum concentration, the highest transfections were observed with 0.01% FA-Cys-PEG-PE (ie similar to the PC/Chol-based formulations). Aside from the probability that the folates could self-associate at high concentrations, it is also very possible that FR interactions were perturbed in the presence of both the cationic lipids and the serum. In other words, the cationic lipids in the formulation could have affected the presentation of folate molecules. However, such interference could have been reduced at high serum levels, where serum proteins could more effectively 'coat' or block the cationic charges of the lipids.
When targeted cationic liposomes were tested in the L1210A intraperitoneal tumor model, the greatest targeted transfections were again produced with formulations containing low amounts (0.01%) of FA-Cys-PEG-PE (ie similar to what we observed with cells incubated in 60% serum in vitro). As reported elsewhere, 38, 39 nontargeted and pegylated control cationic liposomes were found to transfect the luciferase gene into the intraperitoneal tumors and not into the other peritoneal organs. The lack of efficient transfection of normal peritoneal organs is not that surprising because these organs are known to be covered by the peritoneum and underlying connective tissue, both of which constitute additional barriers against the entry of lipid/DNA complexes through the organ surface. 40, 41 In contrast, a disseminated peritoneal tumor is devoid of such coverings, so the cancer cells are more easily accessible to the formulations. 40, 41 Additionally, the transduced gene is more readily expressed in the rapidly proliferating cancer cells rather than in the normal cells that display low mitogenic activity. 42 Thus, when injected i.p., the cationic liposomes can efficiently target peritoneal tumors. We found that in all cases folate targeting increased the transfection activity in the L1210A tumor by at least 10-fold over that produced by the non-targeted control formulations. Furthermore, the transgene was preferentially expressed in both the ascites cells and solid L1210A tumor tissue, whereas the gene expression was very low or undetectable in the various organs located in the peritoneal region. Interestingly, we did observe low levels of transfection activity in the spleens from animals receiving the folate-targeted liposomes (see Figure 5b) ; however, this was not surprising because the FR-positive L1210A tumor cells are known to metastasize to the spleen. In fact, we have confirmed this phenomenon by visually detecting L1201A tumor cells in spleens (using laserassisted optical imaging techniques) of mice injected with a folate-fluorescein molecule (manuscript submitted). Collectively, these data suggest that although non-targeted cationic liposomes facilitate the uptake and expression of DNA in tumor cells in vitro and in vivo, incorporation of the FA-Cys-PEG-PE targeting ligand within the liposomal formulation clearly enhances the overall tumor transfection efficiency.
It was recently shown that both the Marburg and Ebola viruses can transduce a wide variety of normal cell types specifically through their FRs. 43 Yet we have found that folate-targeted lipid/DNA particles apparently do not efficiently transfect normal tissues. One possible explanation for this discrepancy is that these viruses have evolved into the most efficient transduction systems known to man. They are highly effective in their ability to (1) bind cells; (2) release their nucleic acid from within the endosome and into the target cell's cytoplasm; and (3) further transport their genetic material into the host cell's nucleus. Compounded with these features is the viruses' ability to replicate within the compromised cells and then spread to other neighboring cells. Therefore, both Marburg and Ebola virons could conceivably transduce cells that express low (or barely detectable) levels of the FR. Although synthetic lipid-based vectors (such as the aforementioned folate-targeted formulations) have been designed to mimic some of these viral features, the high transfection efficiency of viruses has not yet been achieved. Thus, it is our belief that detection of any significant amount of gene expression is only possible in cells that express relatively high levels of the FR. Consequently, the two possible target tissues that do express high amounts of the FR in our model are the kidneys and the tumor. Although FRs in the tumor are accessible to our folate-targeted formulations, the same is not true with the kidneys since large complexes (ie lipid/DNA particles) are not filtered through the kidneys and thus never come into contact with the apically oriented FRs of the proximal tubules. 18, 44 In conclusion, we have confirmed the observations of other laboratories that folate-mediated endocytosis can be successfully exploited to target transgenes to FRexpressing cancer cells. We have also demonstrated that having a targeting ligand, such as FA-Cys-PEG-PE, in cationic liposome formulations can significantly improve the transfection efficiency of a cationic liposomal formulation. By carefully formulating the liposomal vector with an optimal amount of FA-Cys-PEG-PE, efficient transgene expression was possible in FR-bearing cells both in vitro and in vivo. Since peritoneal cancers often become disseminated during the advanced stages of tumor progression, particularly in ovarian cancer, FA-targeted cationic lipid gene therapy may offer a more effective alternative to conventional chemotherapy.
Materials and methods
Lipid synthesis RPR209120 was synthesized as previously described. 26, 27 Synthesis of folic acid-cysteine-PEG 3400 -distearylphosphatidylethanolamine (FA-Cys-PEG-PE) or folic acidDap-Asp-cysteine-PEG 3400 -distearylphosphatidylethanolamine (FA-Dap-Asp-PEG-PE) was achieved by placing 110 mg (147 mol in 5.5 ml CHCl 3 ) of 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine plus 10 ml of additional CHCl 3 in a 50 ml round bottom flask. Two equivalents of triethylamine were added along with 500 mg NHS-PEG 3,400 -MAL powder (147 mol; Shearwater Polymers, Huntsville, AL, USA). The solution was heated at 60°C for 30 s to clear the solution, and it was then stirred for 2 h at room temperature. The progress of the reaction was followed by thin layer chromatography using chloroform/methanol/water (65:25:4) as eluant. This step typically proceeds to near completion and the product need not be further purified. A 1.5-fold molar excess of folate-␥-cysteine (120 mg) 37 or FA-Dap-Asp-Cys (109 mg) along with five additional equivalents of triethylamine were added to the flask, and the mixture was stirred overnight under argon at room temperature. The solution was filtered through a fine Buchner filter apparatus, and the filtrate was evaporated to minimal volume under reduced pressure. The concentrated solution was next added drop-wise to 100 ml of ether, with constant stirring and then placed on ice for 10 min. Following a 2000 g centrifugation step for 10 min at 4°C, the crude precipitate was washed twice with excess ether. The crude powder was then dissolved in~5 ml of deionized water to form a clear yellow micellar solution. This solution was dialyzed for three cycles in 100 kDa molecular weight cutoff tubing at room temperature against 200 volumes of deionized water for a minimum of 8 h per cycle. The retentate was then lyophilized to dryness, and purity was confirmed by thin layer chromatography (FA-Cys-PEG-PE:
R f = 0.3 (silica gel in 65:25:4 chloroform/methanol/water) and FA-Dap-Asp-Cys-PEG-PE: R f = 0.2 (cellulose in 90:10 methanol/water).
Liposome preparation FA-derivatized liposomes were constructed by incorporating the FA tethered lipid and non-targeted PEG-DOPE at the required mole percentages in a 65:35 molar mixture of egg phosphatidylcholine (PC) and cholesterol (Chol). Briefly, 15 mg of PC, 4.2 mg of Chol (Avanti Polar Lipids, Alabaster, AL, USA), FA-lipid and/or DSPE-PEG were dissolved in 1 ml of chloroform. The lipids were dried under reduced pressure to form a thin film and then hydrated in 0.6 ml of 20 mM calcein in PBS, pH 7.4. The suspension was subjected to 10 cycles of freezing and thawing and then extruded 10 times through a 100 nm polycarbonate membrane (Nuclepore, Pleasanton, CA, USA). The resulting calcein-loaded liposomes were then separated from free calcein on a Sepharose CL-4B column (Pharmacia, Uppsala, Sweden) pre-equilibrated with PBS. The final lipid concentration was~20 mg/ml.
Uptake of FA-Cys-PEG-PE containing liposomes by cells
Fifty l of calcein-loaded FA-Cys-PEG-PE containing liposomes were diluted in 1 ml of FDMEM and then added to monolayers of M109 cells. The cells were incubated at 37°C for 4 h, washed three times with PBS, and then examined under an Olympus phase-contrast/ fluorescence microscope. To quantitatively determine the cell-associated fluorescence, cells were lysed in 1 ml of lysis buffer (1% Triton X-100 in PBS), and the lysis buffer extract was measured in an Aminco Bowman Series 2 fluorescence spectrophotometer. Protein content was estimated by using the bicinchonic acid protein assay (Pierce, Rockford, IL, USA), and results were expressed as fluorescence units per mg of lysate protein.
Plasmid DNA Plasmid DNA contained the luciferase reporter gene under the CMV promoter. Purified plasmid DNA met the following quality criteria: Endotoxin levels Ͻ20 EU/mg; amount supercoiled DNA >90%; E. coli DNA contamination Ͻ5%; RNA contamination Ͻ5%; protein contamination Ͻ1%.
Preparation of cationic liposome/DNA complexes
Liposomes for transfection studies were prepared by drying a chloroform solution of RPR209120 (2 moles), DOPE (2 moles) and FA-Cys-PEG 3400 -PE or PEG 3000 -DOPE, under vacuum to a thin film. The film was hydrated by addition of 1.0 ml of filter-sterilized 5% dextrose in 5 mM HEPES, pH 8.0. Liposomes were prepared by first vortexing the hydrated lipid for 1 min and then subjecting it to sonication in a bath sonicator until a clear emulsion was obtained. DNA was diluted in distilled water and mixed with diluted protamine at a weight ratio of 0.8 mg of protamine per mg of DNA. 45 The mixture was allowed to stand at room temperature for 10 min. Liposome/protamine/DNA complexes were induced to self-assemble by vortexing equal volumes of the RPR20/DOPE suspension and appropriate amounts of DNA/protamine mixture dissolved in sterile 5% dextrose, 5 mM HEPES, pH 8 for 1 min, to yield a final concentration of 5 nmoles RPR209120 per g of DNA. The sizes of the complexes were measured at 20°C by dynamic laser light-scattering detector using a Coulter N4plus particle sizer (Coulter Electronics, Hialeah, FL, USA). The measurements were made at a scattering angle of 90 after dilution of the particles in 5% dextrose.
Transfections M109 cells were seeded at a density of 1 × 10 4 cells/well in 96-well plates (Corning Costar, Cambridge, MA, USA) and maintained for 40-48 h before transfection in folate deficient-RPMI medium 1640 (FDRPMI; Life Technologies, Carlsbad, CA, USA) supplemented with 10% heatinactivated fetal bovine serum (HIFBS). RPR209120/ DOPE liposomes in 5% dextrose were diluted with FDRPMI containing either 10 or 60% FBS or 60% HIFBS, to a final concentration of 1 g of DNA per ml for transfection. After 4 h of transfection, the medium was removed and replaced with fresh medium containing 10% HIFBS, and the cells were maintained for an additional 40 h. Cells were harvested using 50 l of reporter lysis buffer, and the luciferase activity was determined using the Luciferase Assay Reagent (Promega, Madison, WI, USA) and a 96-well MLX microtiter plate luminometer (Dynex Technologies, Chantilly, VA, USA).
Tumor cell inoculation and in vivo administration
Female DBA mice, 6-8-week-old (Harlan, Indianapolis, IN, USA), were maintained on a standard 12-h light-dark cycle and fed ad libitum with folate-deficient chow (Dyets, Bethlehem, PA, USA). Since normal rodent chow contains a high concentration of folic acid (6 mg/kg chow), mice used in these studies were maintained on the folate-free diet for 2 weeks before tumor implantation to achieve serum folate concentrations close to the range of normal human serum. 46 FR-positive murine L1210A leukemia cells were grown in FDRPMI 1640 with 10% HIFBS at 37°C in a 5% CO 2 humidified atmosphere. For tumor cell inoculation, 2 × 10 4 L1210A cells in 400 l were injected intraperitoneally per mouse.
In vivo transfections and analysis of luciferase activity
Liposome-DNA complexes (400 l) were injected into tumor-bearing mice 10 days after tumor cell inoculation, with each mouse receiving 50 g of plasmid DNA. The DNA:lipid ratio (g of DNA/nmol of total lipid) was 1:5 for all RPR209120:DOPE liposomes. These DNA:lipid ratios were selected on the basis of previous studies that suggested that optimal expression of cells in vitro occurred at ratios between 1:4 and 1:7 (data not shown). Twenty-four hours after injection, each mouse was killed and its peritoneal cavity was lavaged with 8 ml of Hanks' balanced salt solution. Ascites cells were recovered by Gene Therapy centrifugation of the peritoneal lavage fluid at 400 g for 10 min. Tumor, liver, spleen and intestine were also excised, weighed and stored at Ϫ70°C until assayed for luciferase activity. Tissue extracts were prepared by adding reporter lysis buffer at a volume to weight ratio of 5 l/mg of the collected organs. Each organ was homogenized for 1 min on ice utilizing a PowerGen 125 unit (Fisher Scientific, Racine, WI, USA) at maximum speed (20 000 r.p.m). Samples were then subjected to three freeze/thaw cycles, spun for 10 min at 12 000 r.p.m. in a microcentrifuge, and 20 l of the supernatant was analyzed for luciferase activity. Protein content was estimated by using the bicinchonic acid protein assay, and results were expressed as fluorescence units per mg of lysate protein.
